Skip to main content

Table 3 Multivariate analysis of PFS and OS (A) – un-stratified, (B) – stratified by treatment line, including interaction of NLR and BDX008

From: Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations

  PFS OS
P HR (95% CI) P HR (95% CI)
A
 BDX008 (+ vs -) 0.031 0.51 (0.28–0.94) 0.009 0.42 (0.21–0.81)
 BRAF (MUT vs WT) 0.895 0.96 (0.50–1.85) 0.793 1.09 (0.56–2.14)
 Linea (> 2 vs 2) 0.016 2.35 (1.17–4.71) 0.008 3.01 (1.33–6.82)
 LDH (highb vs low) 0.027 2.26 (1.10–4.67) 0.011 2.60 (1.24–5.43)
 LDH (n/a vs lowb) 0.322 1.53 (0.66–3.56) 0.332 1.56 (0.63–3.86)
B
 BDX008 (+ vs -) 0.096 0.57 (0.29–1.11) 0.002 0.32 (0.15–0.66)
 NLR ≥5 vs < 5 0.183 1.57 (0.81–3.03) 0.592 1.20 (0.61–2.37)
 BDX008*NLR interaction 0.041 3.57 (1.06–12.03) 0.004 6.53 (1.82–23.45)
  1. aLine of anti-PD-1 therapy
  2. bHigh LDH > 2 ULN, Low LDH < 2 ULN